Plain-English translation of NCT03223610 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a combination of five medications—, , , , and lenalidomide (together called ViPOR)—to treat B-cell lymphomas that have returned or stopped responding to standard chemotherapy. The trial is designed in two phases: first, researchers will find the safest dose of the medication combination, and then they will test how well it works for different types of lymphoma.
While standard chemotherapy combined with certain antibodies has helped many lymphoma patients, some people's cancers come back or never respond to these treatments. Researchers believe that targeting specific pathways cancer cells use to survive may help patients whose cancers are resistant to conventional therapy.
You likely qualify if…
You likely don't qualify if…
You will receive the medication combination in cycles over about six months, either starting with four medications and adding the fifth medication in later cycles, or taking all five medications from the start. During the study, you will have regular clinic visits, blood tests, and imaging scans to monitor how you are responding and to check for any side effects. The trial takes place at a single center and requires ongoing commitment to treatment and follow-up assessments.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States